Last updated: 11/03/2018 15:00:26
Insulin resistance as primary pathogenesis in newly diagnosed, drug naïve type 2 diabetes patients in KoreaSURPRISE
Clinicaltrials.gov ID
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Finalized
Finalized
Trial overview
Official title: Insulin resistance as primary pathogenesis in newly diagnosed, drug naïve type 2 diabetes patients in Korea
Trial description: The purpose of this study is investigating the clinical characteristics of newly diagnosed, drug naïve type 2 diabetic patients according to insulin secretion and insulin resistance.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
insulin resistance assessed using HOMA-IR
Timeframe: within 3months after DM diagnosis
Secondary outcomes:
proportion of patients with severe insulin deficiency assessed using C-peptide
Timeframe: within 3months after DM diagnosis
proportion of metabolic syndrome in patients
Timeframe: within 3months after DM diagnosis
proportion of obesity in patients
Timeframe: within 3months after DM diagnosis
Interventions:
Other: HOMA-IR
Enrollment:
1439
Observational study model:
Other
Primary completion date:
Not applicable
Time perspective:
Prospective
Clinical publications:
Not applicable
Medical condition
Diabetes Mellitus, Type 2
Product
Not applicable
Collaborators
Not applicable
Study date(s)
September 2009 to May 2010
Type
Observational
Phase
Not applicable
Participation criteria
Sex
Female & Male
Age
18+ years
Accepts healthy volunteers
No
- Newly diagnosed, drug naïve type 2 DM patients who gave informed consent, Diagnosis of type 2 DM will be made according to ADA guideline 2009
- Patients age under 18 years
Inclusion and exclusion criteria
Inclusion criteria:
- Newly diagnosed, drug naïve type 2 DM patients who gave informed consent, Diagnosis of type 2 DM will be made according to ADA guideline 2009
Exclusion criteria:
- Patients age under 18 years
Trial location(s)
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Recruitment status
Finalized
Actual primary completion date
Not applicable
Actual study completion date
2010-27-05
Plain language summaries
Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website